Targeting B-cell maturation antigen for treatment and monitoring of relapsed/refractory multiple myeloma patients: a comprehensive review

• Published in: Therapeutic advances in hematology Vol. 15; p. 20406207241275797
• Main Authors: Yashar, David, Regidor, Bernard, Goldwater, Marissa-Skye, Bujarski, Sean, Del Dosso, Ashley, Berenson, James R
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01.01.2024; SAGE Publishing
• Subjects: Systematic Review; multiple myeloma; B-cell maturation antigen (BCMA); serum BCMA; bispecific antibodies; Cchimeric antigen receptor T-cell therapies
• ISSN: 2040-6207; 2040-6215
• DOI: 10.1177/20406207241275797

Despite major therapeutic advancements in recent years, multiple myeloma (MM) remains an incurable disease with nearly all patients experiencing relapsed and refractory disease over the course of treatment. Extending the duration and durability of clinical responses will necessitate the development of therapeutics with novel targets that are capable of robustly and specifically eliminating myeloma cells. B-cell maturation antigen (BCMA) is a membrane-bound protein expressed predominantly on malignant plasma cells and has recently been the target of several novel therapeutics to treat MM patients. This review will focus on recently approved and currently in development agents that target this protein, including bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies. In addition, this protein also serves as a novel serum biomarker to predict outcomes and monitor disease status for MM patients; the studies demonstrating this use of BCMA will be discussed in detail.